CEGE value = 626M
Owns 12% of ABGX = $422M
Cash = $496M
Message 13601712
Profile: Cell Genesys, Inc. is engaged primarily in the development and commercialization of gene therapies to treat major, life-threatening diseases, including cancer and AIDS. Cell Genesys currently has two gene therapy programs, the clinical programs and the pre-clinical programs. The clinical programs include GVAX(tm) cancer vaccines in Phase I/II studies to treat specific types of cancer, such as lung and prostate cancers, and T cell gene therapy for AIDS, which is undergoing Phase II testing. The pre-clinical programs include potential gene therapies for cancer, cardiovascular disorders, hemophilia and Parkinson's disease. Cell Genesys also develops and commercializes, through its partially owned subsidiary, Abgenix, Inc., human monoclonal antibodies for pharmaceutical applications, including inflammation, autoimmune disorders and cancer.
Check the numbers might not be 100% correct.
siliconinvestor.com |
